about
sameAs
Scientific Lenses to Support Multiple Views over Linked Chemistry DataChemical databases: curation or integration by user-defined equivalence?The ChEMBL bioactivity database: an updateUniChem: extension of InChI-based compound mapping to salt, connectivity and stereochemistry layersManaging expectations: assessment of chemistry databases generated by automated extraction of chemical structures from patentsTransporter assays and assay ontologies: useful tools for drug discoveryUniChem: a unified chemical structure cross-referencing and identifier tracking systemThe EBI RDF platform: linked open data for the life sciencesChEMBL: a large-scale bioactivity database for drug discoveryChemical, target, and bioactive properties of allosteric modulationThe ChEMBL database in 2017A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand target space in ChEMBLActivity, assay and target data curation and quality in the ChEMBL databaseA large-scale crop protection bioassay data setChEMBL web services: streamlining access to drug discovery data and utilitiesPSICQUIC and PSISCORE: accessing and scoring molecular interactionsMotif3D: Relating protein sequence motifs to 3D structure.Functional assignment of MAPK phosphatase domains.Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns.Collation and data-mining of literature bioactivity data for drug discovery.PRINTS and its automatic supplement, prePRINTS.Minimum information about a bioactive entity (MIABE).Bioinformatics approaches for the classification of G-protein-coupled receptors.The complex portal--an encyclopaedia of macromolecular complexesPPDMs-a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains.Using ChEMBL web services for building applications and data processing workflows relevant to drug discovery.SureChEMBL: a large-scale, chemically annotated patent document database.Open Targets: a platform for therapeutic target identification and validationPharos: Collating protein information to shed light on the druggable genome.Visualizing the drug target landscape.Visualizing the drug target landscape.Drug target central.Transporter taxonomy - a comparison of different transport protein classification schemes.A comprehensive map of molecular drug targets.PRINTS and PRINTS-S shed light on protein ancestryRole of open chemical data in aiding drug discovery and design.The druggable genome and support for target identification and validation in drug development.Unexplored therapeutic opportunities in the human genome.Deriving structural and functional insights from a ligand-based hierarchical classification of G protein-coupled receptorsShouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group
P50
Q23034460-A14C99EA-F17F-41B8-B569-9D2F50CB7E88Q26801611-F0B1F699-F639-4B8A-97EC-2C4033F26256Q27144224-EF23B8B2-CA4F-4DBF-9EE1-7196FBC7BEC9Q27902274-95002823-37EC-4F72-9889-9ADB1BF9BAFCQ27902313-91BEC762-390E-44DF-BD7B-E0278518505FQ27967890-A5FBF797-4AAD-43F3-A97C-6F4EB2853074Q28133251-B7E6DA8A-7A5E-4B0D-A22D-D3412CF859E9Q28305672-D55B3A72-944F-4C8D-A53D-DADED6BC3475Q28315179-402D74BA-150A-46E2-8740-CCF056AC7EC8Q28541837-84575BF3-9270-426C-8F5E-B5C4EEACDCA8Q28584450-16FA7BEF-FC9A-4C84-ACFA-A4DBE9CA28E9Q28598307-5489E843-53D8-47F4-A88F-D5A443437CB3Q28611248-AD341B44-2926-4147-97D9-2DCC5091E557Q28647441-8796403C-D6D5-4954-A45E-7DFF5740DD99Q28647641-D2489C2E-EF3E-400A-A66E-3F60439F170AQ28740880-16F439B2-8BAB-4B43-AEB3-DB7E349A25DCQ30333050-524D2676-4B53-4538-9F98-ABAEC8A1F3C5Q31116991-BEF39522-D73F-4E9A-9CCD-D2CB0B9E2545Q31202630-2B93068F-B546-4AD2-83A9-FEE061E1DADCQ34026765-F70EA183-2E8F-46CD-945F-6487EF46960EQ34169535-85450199-917B-42CA-B101-05A09CC915F5Q34212022-9AEE103D-5C2A-43DF-A244-BF96F3EDBB0CQ35101686-B7BB53DB-6C4B-46E6-925F-6D0273CD27BCQ35254891-D5FC60B9-5927-4454-B143-60E8FEECE135Q35369278-4BAEA168-809A-4D9B-949A-BBBBD7270B53Q36397674-966C09BA-4D18-4617-B319-A11220E148AEQ36434910-198FC399-6DED-41EB-B818-8E05566C80B7Q37556749-BE05CCFD-CC96-4B64-A354-85881545C83CQ37556791-97D1AB3B-D9BD-451A-8C34-CBD4E30FA68FQ37617737-1BC0E431-4E04-4E52-BAC0-FA4340654FDCQ37969533-5E73CFB7-48A6-4776-B54F-AF0C67F31E50Q38089909-FC8006F4-C3E3-49E5-B32B-55CA777BFEB4Q38474772-3C715D37-5B27-4D8B-AA31-1B4E641BBB08Q39026969-186938B7-098D-49A9-A8C3-65A7D475FEC8Q39524544-6FEC118C-2293-41B9-A6A5-FE39188ED6E8Q42594717-08134600-E56F-49ED-99E9-25BC6B54A25BQ48347170-75C524B5-DAAA-4FC5-9D0C-2C0AEE1CBD39Q52689109-2C594642-8EA4-4702-B8F0-1ACDF17BC616Q56835962-BAAA46A8-1A12-48E1-B230-05B62EE07345Q56881081-721198FD-CC28-4875-B3F4-82887F671EDB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Gaulton
@ast
Anna Gaulton
@en
Anna Gaulton
@es
Anna Gaulton
@nl
Anna Gaulton
@sl
type
label
Anna Gaulton
@ast
Anna Gaulton
@en
Anna Gaulton
@es
Anna Gaulton
@nl
Anna Gaulton
@sl
prefLabel
Anna Gaulton
@ast
Anna Gaulton
@en
Anna Gaulton
@es
Anna Gaulton
@nl
Anna Gaulton
@sl
P106
P21
P2456
P31
P496
0000-0003-2634-7400